Chronic myelogenous leukemia other diagnostic studies: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 5: Line 5:


==Biopsy==
==Biopsy==
A [[bone marrow biopsy]] is often performed as part of the evaluation for CML, but bone marrow morphology alone is insufficient to diagnose CML.<ref name="Hehlmann"/><ref name="Tefferi"/>
A [[bone marrow biopsy]] is often performed as part of the evaluation for CML, but bone marrow morphology alone is insufficient to diagnose CML.


==Philadelphia chromosome==
==Philadelphia chromosome==
Ultimately, CML is diagnosed by detecting the [[Philadelphia chromosome]]. This characteristic chromosomal abnormality can be detected by routine [[cytogenetics]], by [[fluorescent in situ hybridization]], or by [[PCR]] for the bcr-abl fusion gene.<ref name="Tefferi"/>
Ultimately, CML is diagnosed by detecting the [[Philadelphia chromosome]]. This characteristic chromosomal abnormality can be detected by routine [[cytogenetics]], by [[fluorescent in situ hybridization]], or by [[PCR]] for the bcr-abl fusion gene.


[[Image:CDR533336-571.jpg|thumb|center|450px|[[Philadelphia chromosome]]. A piece of chromosome 9 and a piece of chromosome 22 break off and trade places. The bcr-abl gene is formed on chromosome 22 where the piece of chromosome 9 attaches. The changed chromosome 22 is called the [[Philadelphia chromosome]] [http://www.cancer.gov/cancertopics/pdq/treatment/CML/patient/ Source].]]
[[Image:CDR533336-571.jpg|thumb|left|200px|[[Philadelphia chromosome]]. A piece of chromosome 9 and a piece of chromosome 22 break off and trade places. The bcr-abl gene is formed on chromosome 22 where the piece of chromosome 9 attaches. The changed chromosome 22 is called the [[Philadelphia chromosome]]{{-}}
 
[http://www.cancer.gov/cancertopics/pdq/treatment/CML/patient/ Source].]] {{-}}


Controversy exists over so-called ''Ph-negative'' CML, or cases of suspected CML in which the Philadelphia chromosome cannot be detected. Many such patients in fact have complex chromosomal abnormalities which mask the (9;22) translocation, or have evidence of the translocation by [[fluorescent in situ hybridization|FISH]] or [[RT-PCR]] in spite of normal routine karyotyping.<ref>{{cite journal|title=Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period|author=Savage DG; Szydlo RM; Goldman JM|journal=Br J Haematol|date=1997|volume=96|issue=1|pages=111-116|pmid=9012696}}</ref> The small subset of patients without detectable molecular evidence of bcr-abl fusion may be better classified as having an undifferentiated myelodysplastic/myeloproliferative disorder, as their clinical course tends to be different from patients with CML.<ref name="WHO">{{cite journal|title=Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert pane|author=Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW|date=2007|journal=Blood|volume=110|issue=4|pages=1092-1097|pmid=17488875}}</ref>
Controversy exists over so-called ''Ph-negative'' CML, or cases of suspected CML in which the Philadelphia chromosome cannot be detected. Many such patients in fact have complex chromosomal abnormalities which mask the (9;22) translocation, or have evidence of the translocation by [[fluorescent in situ hybridization|FISH]] or [[RT-PCR]] in spite of normal routine karyotyping.<ref>{{cite journal|title=Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period|author=Savage DG; Szydlo RM; Goldman JM|journal=Br J Haematol|date=1997|volume=96|issue=1|pages=111-116|pmid=9012696}}</ref> The small subset of patients without detectable molecular evidence of bcr-abl fusion may be better classified as having an undifferentiated myelodysplastic/myeloproliferative disorder, as their clinical course tends to be different from patients with CML.<ref name="WHO">{{cite journal|title=Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert pane|author=Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW|date=2007|journal=Blood|volume=110|issue=4|pages=1092-1097|pmid=17488875}}</ref>


<div align="left">
<div align="left">

Revision as of 16:07, 20 January 2012

Chronic myelogenous leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chronic myelogenous leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic myelogenous leukemia other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic myelogenous leukemia other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic myelogenous leukemia other diagnostic studies

CDC on Chronic myelogenous leukemia other diagnostic studies

Chronic myelogenous leukemia other diagnostic studies in the news

Blogs on Chronic myelogenous leukemia other diagnostic studies

Directions to Hospitals Treating Chronic myelogenous leukemia

Risk calculators and risk factors for Chronic myelogenous leukemia other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Biopsy

A bone marrow biopsy is often performed as part of the evaluation for CML, but bone marrow morphology alone is insufficient to diagnose CML.

Philadelphia chromosome

Ultimately, CML is diagnosed by detecting the Philadelphia chromosome. This characteristic chromosomal abnormality can be detected by routine cytogenetics, by fluorescent in situ hybridization, or by PCR for the bcr-abl fusion gene.

Philadelphia chromosome. A piece of chromosome 9 and a piece of chromosome 22 break off and trade places. The bcr-abl gene is formed on chromosome 22 where the piece of chromosome 9 attaches. The changed chromosome 22 is called the Philadelphia chromosome
Source.

Controversy exists over so-called Ph-negative CML, or cases of suspected CML in which the Philadelphia chromosome cannot be detected. Many such patients in fact have complex chromosomal abnormalities which mask the (9;22) translocation, or have evidence of the translocation by FISH or RT-PCR in spite of normal routine karyotyping.[1] The small subset of patients without detectable molecular evidence of bcr-abl fusion may be better classified as having an undifferentiated myelodysplastic/myeloproliferative disorder, as their clinical course tends to be different from patients with CML.[2]

References

  1. Savage DG; Szydlo RM; Goldman JM (1997). "Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period". Br J Haematol. 96 (1): 111–116. PMID 9012696.
  2. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007). "Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert pane". Blood. 110 (4): 1092–1097. PMID 17488875.


Template:WikiDoc Sources